» Articles » PMID: 28819352

Metabolomics of Biomarker Discovery in Ovarian Cancer: a Systematic Review of the Current Literature

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2017 Aug 19
PMID 28819352
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Metabolomics is the emerging member of "omics" sciences advancing the understanding, diagnosis and treatment of many cancers, including ovarian cancer (OC).

Objectives: To systematically identify the metabolomic abnormalities in OC detection, and the dominant metabolic pathways associated with the observed alterations.

Methods: An electronic literature search was performed, up to and including January 15th 2016, for studies evaluating the metabolomic profile of patients with OC compared to controls. QUADOMICS tool was used to assess the quality of the twenty-three studies included in this systematic review.

Results: Biological samples utilized for metabolomic analysis include: serum/plasma (n = 13), urine (n = 4), cyst fluid (n = 3), tissue (n = 2) and ascitic fluid (n = 1). Metabolites related to cellular respiration, carbohydrate, lipid, protein and nucleotide metabolism were significantly altered in OC. Increased levels of tricarboxylic acid cycle intermediates and altered metabolites of the glycolytic pathway pointed to perturbations in cellular respiration. Alterations in lipid metabolism included enhanced fatty acid oxidation, abnormal levels of glycerolipids, sphingolipids and free fatty acids with common elevations of palmitate, oleate, and myristate. Increased levels of glutamine, glycine, cysteine and threonine were commonly reported while enhanced degradations of tryptophan, histidine and phenylalanine were found. N-acetylaspartate, a brain amino acid, was found elevated in primary and metastatic OC tissue and ovarian cyst fluid. Further, elevated levels of ketone bodies including 3-hydroxybutyrate were commonly reported. Increased levels of nucleotide metabolites and tocopherols were consistent through out the studies.

Conclusion: Metabolomics presents significant new opportunities for diagnostic biomarker development, elucidating previously unknown mechanisms of OC pathogenesis.

Citing Articles

Butyrate as a Potential Modulator in Gynecological Disease Progression.

Kim N, Yang C Nutrients. 2024; 16(23).

PMID: 39683590 PMC: 11644728. DOI: 10.3390/nu16234196.


Untargeted Metabolomic Biomarker Discovery for the Detection of Ectopic Pregnancy.

Turkoglu O, Citil A, Katar C, Mert I, Quinn R, Bahado-Singh R Int J Mol Sci. 2024; 25(19).

PMID: 39408663 PMC: 11476625. DOI: 10.3390/ijms251910333.


Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.

Gralewska P, Gajek A, Marczak A, Rogalska A Int J Mol Sci. 2024; 25(15).

PMID: 39125873 PMC: 11312858. DOI: 10.3390/ijms25158304.


Racial Differences in Vaginal Fluid Metabolites and Association with Systemic Inflammation Markers among Ovarian Cancer Patients: A Pilot Study.

Osazuwa-Peters O, Deveaux A, Muehlbauer M, Ilkayeva O, Bain J, Keku T Cancers (Basel). 2024; 16(7).

PMID: 38610937 PMC: 11011195. DOI: 10.3390/cancers16071259.


Microfluidic production of amiodarone loaded nanoparticles and application in drug repositioning in ovarian cancer.

Saorin A, Saorin G, Duzagac F, Parisse P, Cao N, Corona G Sci Rep. 2024; 14(1):6280.

PMID: 38491077 PMC: 10943008. DOI: 10.1038/s41598-024-55801-3.


References
1.
Chen J, Zhang X, Cao R, Lu X, Zhao S, Fekete A . Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res. 2011; 10(5):2625-32. DOI: 10.1021/pr200173q. View

2.
Jobard E, Pontoizeau C, Blaise B, Bachelot T, Elena-Herrmann B, Tredan O . A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2013; 343(1):33-41. DOI: 10.1016/j.canlet.2013.09.011. View

3.
Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

4.
Schulze A, Harris A . How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012; 491(7424):364-73. DOI: 10.1038/nature11706. View

5.
Falus A . Histamine, part of the metabolome. Acta Biol Hung. 2003; 54(1):27-34. DOI: 10.1556/ABiol.54.2003.1.3. View